Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis
Not Applicable
- Conditions
- Chemotherapy-induced nausea and vomiting
- Registration Number
- JPRN-UMIN000050958
- Lead Sponsor
- Department of Pharmacy, Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Exclude the following 1. Clinical trials comparing different combination regimens including 5-HT3 receptor antagonists and other antiemetics. 2. Incomplete information or data.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete response (CR: defined as no emesis and no rescue medication) rate for delayed CINV, defined as occurring CINV after 24 hours from chemotherapy, between palonosetron and first-generation 5-HT3 receptor antagonist in pediatric patients.
- Secondary Outcome Measures
Name Time Method CR for overall CINV CR for acute CINV, defined as CINV occurring within 24 hours from chemotherapy Incidence of adverse events